Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible, the following inclusion criteria were met:~* History of type 1 diabetes and receiving daily insulin therapy from the time of diagnosis for at least 12 months~* At least 4 years of age and less than 17 years~* Females must have met one of the following criteria:~  * Of childbearing potential but agreed to use an accepted contraceptive regimen as described in the study procedure manual throughout the entire duration of the study (from screening until study completion)~ * Of non-childbearing potential, defined as a female who had a hysterectomy or tubal ligation, was clinically considered infertile or had not yet reached menarche~* In good general health with no conditions that could have influenced the outcome of the trial, and in the judgment of the Investigator was a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations~* Willingness to adhere to the study requirements~Exclusion Criteria:~An individual was not eligible if any of the following exclusion criteria were present:~* Females who were pregnant according to a positive urine pregnancy test, actively attempting to get pregnant, or were lactating~* History of hypersensitivity to glucagon or any related products or severe hypersensitivity reactions (such as angioedema) to any drugs~* Presence of cardiovascular, gastrointestinal, liver or kidney disease, or any other conditions which in the judgment of the investigator could have interfered with the absorption, distribution, metabolism or excretion of drugs or could potentiate or predispose to undesired effects~* History of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma~* History of an episode of severe hypoglycemia (as defined by an episode that required third party assistance for treatment) in the 1 month prior to enrolling in the study~* Use of daily systemic beta-blocker, indomethacin, warfarin or anticholinergic drugs~* History of epilepsy or seizure disorder~* Use of an Investigational Product in another clinical trial within the past 30 days~* Blood donation in 3 months prior to first glucagon dosing

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Nasal Glucagon (NG) (Type: EXPERIMENTAL): Nasal glucagon (NG) doses of 2.0 mg and 3.0 mg for participants 4 to less than 12 years of age and 3.0 mg for those 12 to less than 17 years of age were administered in a nostril with a prefilled delivery device that delivered a single dose upon activation.
- Intramuscular (IM) Glucagon (Type: ACTIVE_COMPARATOR): Participants who weighed at least 25 kilograms (kg)/55 pounds (lbs) were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 lbs, IM glucagon dosed with 0.5 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).